Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Regeneron's antibody therapy cuts deaths among some hospitalised COVID-19 patients -study

Stock MarketsJun 16, 2021 01:04PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: A patient suffering from COVID-19 receives treatment at the coronavirus disease (COVID-19) Intensive Care Unit (ICU) of the "Klinikum Darmstadt" clinic in Darmstadt, Germany, May 20, 2021. REUTERS/Kai Pfaffenbach/File Photo 2/2

By Alistair Smout

LONDON (Reuters) - A COVID-19 antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche reduced deaths in hospitalised patients whose own immune systems had failed to produce a response, a large British study found on Wednesday.

The therapy, REGEN-COV, has been granted emergency use authorisation for people with mild-to-moderate COVID-19 in the United States, but results from the RECOVERY trial provide the clearest evidence of its effectiveness among hospitalised patients.

It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with COVID-19 whose immune system had not mounted an antibody response, known as seronegative.

The result translates into six fewer deaths for every 100 seronegative patients treated with the therapy, researchers said.

There was no discernible effect of the treatment on those who had generated natural antibody responses.

"People have been very, very sceptical, that any treatment against this particular virus would work by the time people get in hospital," Martin Landray, the joint chief investigator on the trial, told reporters.

"If you haven't raised antibodies of your own, you really would benefit from getting some," he said.

The treatment also shortened the hospital stay of those who were seronegative and reduced their chances of needing a mechanical ventilator, Landray said.

Regeneron had previously said its treatment had shown enough promise in hospitalised patients to warrant continuing its trial. This data provides the first large-scale confirmation of that assertion.

There were 9,785 patients hospitalised with COVID-19 who were randomly allocated to receive usual care plus the antibody combination therapy or just usual care, of which 30% were seronegative.

The RECOVERY trial also showed the steroid dexamethasone and Roche's arthritis drug Actemra (tocilizumab) cut deaths in hospitalised patients.

While those treatments focus on inflammation caused by reaction to the coronavirus, Regeneron's therapy, which belongs to a class of biotech drugs called monoclonal antibodies, mimic natural antibodies the body produces to fight off the infection.

"This is the first time we've got one that's actually targeting the virus itself," Landray said, adding that it could be used along with the other treatments.

"It's not that you do one thing or another thing. These benefits are additive in these patients," he said.

POSSIBILITY FOR OTHERS

Other companies have been developing similar treatments.

U.S. emergency use authorization has been granted to antibody treatments developed by Eli Lilly (NYSE:LLY) and Co as well as by Vir Biotechnology (NASDAQ:VIR) Inc with GlaxoSmithKline (NYSE:GSK) Plc. Both are approved for use in mild-to-moderate cases.

On Tuesday, AstraZeneca (NASDAQ:AZN) said its antibody therapy had shown no evidence of protecting people from developing the disease following exposure, although other trials of its cocktail as a prevention or a treatment are ongoing.

Landray said the RECOVERY results should give developers of other monoclonal antibody therapies optimism that they can also be used in some hospitalised patients.

"This opens up the possibility for many, many others," he said.

"People see a few negative trials and they say 'well that'll never work' and they opt out and go off and do something else. (But) this is very, very clear, the picture that we've got from this trial."

Regeneron has enlisted Swiss pharmaceutical Roche to help manufacture the drug.

Some cautioned that the full cost-benefit of the drug would not be clear until more details of the study were available.

"The absolute magnitude of benefit in mortality is not large, and it means that a large (possibly 20) number of people have to be treated with the extremely expensive drug for a single death to be prevented," said Stephen Evans, Professor of Pharmacoepidemiology, London School of Hygiene & Tropical Medicine.

"If (patients) can be readily identified and treated it will have some benefit in practice, but its benefits should not be overstated."

Regeneron's antibody therapy cuts deaths among some hospitalised COVID-19 patients -study
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email